

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

2022 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, collectively the “**Group**”, “**We**” or “**Our**”) for financial year 2022 (the “**2022 Third Quarterly Report**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards issued by the International Accounting Standards Board (the “**IFRSs**”) (as applicable) and has not been audited.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 26, 2022

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Dr. Minzhang Chen, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou, Mr. Xiaotong Zhang and Mr. Dai Feng as independent non-executive Directors.

* *For identification purpose only*

I. Important Notice

- 1.1 The Board, the Supervisory Committee and the Directors, the supervisors and the senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2022 Third Quarterly Report and that there are no false information, misleading statements or material omissions in the 2022 Third Quarterly Report, and shall assume several and joint legal responsibilities.
- 1.2 Ge Li, the person in charge of the Company, Ming Shi, the chief financial officer and Jin Sun, the director of the accounting department (person in charge of accounting) warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2022 Third Quarterly Report.
- 1.3 The 2022 Third Quarterly Report of the Company has not been audited.
- 1.4 Definitions

Definitions of frequently-used terms

“A Share(s)”	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB
“Board”	the board of Directors of the Company
“China” or “PRC”	the People’s Republic of China, which for the purpose of this quarterly report and for geographical reference only, excludes the Hong Kong Special Administrative Region of the PRC, the Macao Special Administrative Region of the PRC and Taiwan
“clinical trial(s)”	systematical investigation of drugs conducted on human subjects (patients or healthy volunteers) to prove or reveal the function, adverse reactions and/or absorption, distribution, metabolism and excretion of the drug being investigated. The purpose of a clinical trial is to determine the therapeutic efficacy and safety of the drug
“CRDMO”	Contract Research Development and Manufacturing Organization
“CRO”	Contract Research Organization

“CSRC”	China Securities Regulatory Commission
“CTDMO”	Contract Testing Development and Manufacturing Organization
“Director(s)”	the director(s) of the Company or any one of them
“end of the Reporting Period”	September 30, 2022
“H Share(s)”	overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on the Stock Exchange
“IFRSs”	International Financial Reporting Standards issued by the International Accounting Standards Board
“IND filing”	filing for clinical trial of investigational new drug (IND), which is necessary before commencement of clinical trial
“Reporting Period”	the period from July 1, 2022 to September 30, 2022
“RMB” or “RMB million”	Renminbi yuan or million yuan
“Share(s)”	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
“SMO”	Site Management Organization
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisory Committee”	the supervisory committee of the Company
“U.S.”	the United States of America, its territories, its possession and all areas subject to its jurisdiction
“WIND”	WuXi IND service platform

II. Company Profile

The Company is a leading global pharmaceutical R&D service platform. As a global company with operations across Asia, Europe, and North America, we provide a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, the Company provides integrated, end-to-end services including chemistry drug CRDMO, biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

As at the end of the Reporting Period, the Company provided services to over 5,900 active customers in over 30 countries through its 32 operating bases and subsidiaries worldwide. As at the end of the Reporting Period, the Company had 45,646 employees, including 13,488 employees with a master's or higher degree and 1,379 employees with a Ph.D. or equivalent degree. A breakdown of our employees by function and by geography is set out below:

Position	Asia	U.S.	Europe	Total
Research and development	36,717	1,120	135	37,972
Manufacturing	4,264	241	92	4,597
Sales	41	83	32	156
Management and administration	2,405	445	71	2,921
Total	<u>43,427</u>	<u>1,889</u>	<u>330</u>	<u>45,646</u>

To maintain the high service standards and industry leading expertise and continuously meet customers' demands, the Company will continue to recruit, train, promote, incentivize and retain talented individuals.

III. Major financial data

1. Major financial statement items and financial indicators

Unit: RMB

Item	For the Reporting Period	Year-over-year increase/decrease (%)	From the beginning of the year to the end of the Reporting Period	Year-over-year increase/decrease (%)
Revenue	10,638,303,791.29	77.76	28,394,561,790.41	71.87
Net profit attributable to the owners of the Company	2,742,164,675.92	209.11	7,377,913,928.98	107.12
Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items	2,382,204,909.91	143.31	6,232,172,714.92	100.64
Net cash flows from operating activities	Not applicable	Not applicable	7,709,650,548.49	142.38
Basic earnings per share (RMB/share)	0.93	210.00	2.52	106.56
Diluted earnings per share (RMB/share)	0.81	170.00	2.30	90.08
Weighted average return on net assets (%)	6.51	Increased by 3.98 percentage points	17.72	Increased by 7.49 percentage points
				Increase/decrease as at the end of the Reporting Period as compared to the end of the previous year (%)
	As at the end of the Reporting Period	As at the end of the previous year		
Total assets	65,749,216,761.50	55,127,388,384.03		19.27
Equity attributable to the owners of the Company	44,810,034,664.07	38,491,509,630.60		16.42

Note:

The “Reporting Period” hereinafter refers to the three-month period from the beginning to the end of the third quarter of 2022.

2. Non-recurring gain or loss items and amounts

Unit: RMB

Item	Amount for the Reporting Period	Amount for the period from the beginning of the year to the end of the Reporting Period	Description
Gain or loss on disposal of non-current assets	-6,236,094.44	-11,888,152.14	
Deemed as investment income from disposal of long-term equity investments	—	125,445,282.28	
Government grants included in profit or loss of the current period (except for those closely related to the Company's normal operation and which were granted on a recurring basis subject to certain amount or volume upon fulfilment of specific standards in compliance with the government policies and regulations)	63,854,489.98	225,067,611.55	
Gain or loss arising from changes in fair value of holding held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities, and investment income from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities, derivative financial liabilities, and other debt investments, except effective hedging business related to the Company's normal operations	329,142,193.68	935,500,812.55	It was mainly due to changes in fair value of non-current financial assets and gains on disposal, and gains from changes in fair value of H share convertible bonds
Other non-operating income and expenses other than the above items	-7,840,757.87	-18,778,375.75	
Less: Effect of income tax	18,422,751.92	108,589,493.31	
Less: Impact on non-controlling interests (after tax)	537,313.42	1,016,471.12	
Total	<u>359,959,766.01</u>	<u>1,145,741,214.06</u>	

Explanation on classifying the non-recurring profit or loss items listed in the “Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Profit or Loss” as recurring profit or loss items

Applicable Not applicable

3. Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

Applicable Not applicable

Item	Change (%)	Main reasons
Revenue for the Reporting Period	77.76	Please refer to the note below for details.
Revenue for the period from the beginning of the year to the end of the Reporting Period	71.87	Please refer to the note below for details.
Net profit attributable to the owners of the Company for the Reporting Period	209.11	
Net profit attributable to the owners of the Company for the period from the beginning of the year to the end of the Reporting Period	107.12	
Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items for the Reporting Period	143.31	It was mainly due to significant growth in operating profit which resulted from continued enhancement of production capacity utilization and operational efficiency.
Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items of the Company for the period from the beginning of the year to the end of the Reporting Period	100.64	
Net cash flows from operating activities for the period from the beginning of the year to the end of the Reporting Period	142.38	Please refer to the note below for details.
Basic earnings per share (RMB/share) for the Reporting Period	210.00	
Basic earnings per share (RMB/share) for the period from the beginning of the year to the end of the Reporting Period	106.56	It was mainly due to the growth in net profit attributable to the owners of the Company in the first three quarters of 2022.
Diluted earnings per share (RMB/share) for the Reporting Period	170.00	
Diluted earnings per share (RMB/share) for the period from the beginning of the year to the end of the Reporting Period	90.08	

Note:

The percentage of change for the Reporting Period refers to the increase or decrease for the Reporting Period as compared with the corresponding period of the previous year. The percentage of change for the period from the beginning of the year to the end of the Reporting Period refers to the increase or decrease for the period from January to September 2022 as compared with the corresponding period of the previous year.

Analysis note:

Revenue

In the first three quarters of 2022, demand for our services was strong and we grew our customer base to more than 5,900 active accounts by adding over 1,000 new customers. Revenue from US-based customers grew 110% to RMB18,991 million; revenue from China-based customers grew 30% to RMB5,318 million; revenue from Europe-based customers grew 21% to RMB2,897 million; and revenue from other regions grew 22% to RMB1,188 million. We continued to expand our customer base and we remain focused on delivering high quality services with great efficiency to retain loyal customers. Revenue from existing clients grew 80% to RMB27,546 million and new clients contributed RMB849 million in revenue. Benefiting from our continuous efforts in the global “long-tail customer” strategy and the increasing penetration rate of other customers, revenue from the top 20 global pharmaceutical companies grew 175% to RMB12,918 million; revenue generated from all other customers grew 31% to RMB15,477 million. Our unique positioning across the pharmaceutical development value chain drove our “follow-the-molecule” strategy and enhanced synergies across our business segments. Customers using services from multiple business units contributed RMB25,915 million in revenue, growing 83% year-over-year.

Unit: Million Currency: RMB

Operating segments	Third quarter of 2022	Third quarter of 2021	Change (%)	First three quarters of 2022	First three quarters of 2021	Change (%)
Chemistry business (WuXi Chemistry)	7,842.5	3,651.4	114.8	20,816.7	10,077.2	106.6
Testing business (WuXi Testing)	1,572.0	1,227.3	28.1	4,177.1	3,334.5	25.3
Biology business (WuXi Biology)	688.7	504.1	36.6	1,779.4	1,424.3	24.9
Cell and gene therapy CTDMO business (WuXi ATU)	306.2	282.5	8.4	921.6	735.9	25.2
Domestic Discovery Service Unit (WuXi DDSU)	216.7	311.1	-30.3	671.8	931.8	-27.9

In the first three quarters of 2022, revenue of the Company was RMB28,394.6 million, representing a year-over-year (YoY) increase of 71.9% while its principal business recorded revenue of RMB28,366.6 million, representing a YoY increase of 71.9% due primarily to the following:

- (1) Our chemistry business (WuXi Chemistry) realized revenue of RMB20,816.7 million in the first three quarters of 2022, representing a YoY growth of 106.6% as compared to the revenue of RMB10,077.2 million in the same period of 2021. Revenue from small molecule drug discovery (R) services amounted to RMB5,394.0 million, representing a YoY growth of 36.2%, and revenue from small molecule development and manufacturing (D&M) services amounted to RMB15,422.7 million, representing a YoY growth of 152.2%. Excluding the COVID-19 commercialization production projects, revenue from chemistry business recorded a YoY growth of 38.3%. The revenue from new modalities grew by 192.5%. We fully leveraged our technological advantage in development and pushed forward the strategy of “follow-the-molecule”. In relation to small molecule drug discovery (R) services, we completed the synthesis of more than 379,000 custom synthesized compounds in the past 12 months, empowering customers of early-stage development of innovative small molecule drugs and serving as an important “funnel entrance” of the Company’s downstream business units. By establishing close collaborative relationships with our customers in drug discovery and preclinical stages based on our “follow-the-customer” and “follow-the-molecule” strategies, we are able to seek opportunities for new projects from late clinical stage to the commercialization stage, facilitating sustainable and rapid growth in revenue from our CRDMO services. The Company continuously implements the long-tail customer strategy

and has recorded robust growth in long-tail customers. In the first three quarters of 2022, we added 692 molecules to the chemistry D&M pipeline, including 1 new molecule at the commercialization stage. As at the end of the third quarter of 2022, our chemistry services involved 2,123 new drug molecules, including 53 in Phase III, 288 in Phase II, 1,738 in Phase I and preclinical stage and 44 drug approvals. In terms of D&M services of new modalities, the number of oligonucleotide and peptide D&M customers under our chemistry business sector was 97, representing a YoY growth of 98%. The number of oligonucleotide and peptide D&M molecules was 155, representing a YoY growth of 101%, with revenue reaching RMB1.1 billion, representing a YoY growth of 406%. Capacity expansion of WuXi Chemistry continued to accelerate to meet demands. In the first three quarters of 2022, we began to operate part of Changzhou Phase 3 facility including a new R&D center and 5 plants. We also announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility in July 2022. The new facility underscores our ongoing commitment to enhancing our capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide. In September 2022, we opened a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility as well as our first high potency oral drug product manufacturing facility at our Wuxi campus, which further enhances our global integrated CRDMO platform capability. In addition, we opened a new campus in Wuhan, continuously expanding our capacity for drug discovery service. In the third quarter of 2022, we also announced the construction plan of a new site in Singapore. We also held a groundbreaking ceremony for our new pharmaceutical manufacturing campus in Middletown, Delaware, USA to serve our global customers' future needs.

- (2) Our testing business (WuXi Testing) realized revenue of RMB4,177.1 million in the first three quarters of 2022, representing a YoY growth of 25.3% as compared to the revenue of RMB3,334.5 million in the same period of 2021. Revenue from lab analysis and testing services amounted to RMB3,042.0 million, representing a YoY growth of 35.2%, and revenue from clinical CRO and SMO amounted to RMB1,135.1 million, representing a YoY growth of 4.6%. The Company provides a full range of laboratory testing services for our customers, including drug metabolism and pharmacokinetics (DMPK), toxicology, and bioanalysis for drug analysis and testing. We leveraged our integrated platform through the WIND service platform, and integrated preclinical pharmacodynamics, pharmacokinetics, safety evaluation, and application writing and filing to provide a one-stop service for customers in respect of new drug R&D and filing globally so as to accelerate their process of new drug R&D. From January to September 2022, 89 service contracts were signed through the WIND service platform. In respect of drug safety evaluation business, revenue maintained significant growth momentum as compared to the same period of last year and realized a YoY growth of 49% in the first three quarters of 2022. We maintained and expanded our industry-leading position in Asia-Pacific for drug safety evaluation services

that meet the highest global regulatory requirements. Testing services for medical devices recovered significantly and recorded a YoY growth of 30% in the first three quarters of 2022. For laboratory testing business, a 55,000 square meters laboratory was under construction in Suzhou and Qidong for mid-2023 delivery. The revenue growth of our clinical CRO and SMO service was slowed, due in part to the ongoing impacts of COVID-19 in many cities across China this year. Meanwhile, our clinical business has rebounded by approximately 95%. In respect of clinical CRO services, despite the challenges this year, from January to September 2022, the Company provided clinical testing and development services to approximately 190 projects, enabling our customers to obtain 10 IND approvals. For clinical SMO services, the Company maintained No.1 leadership position in China and continued to grow, revenue grew 20% in the first three quarters of 2022 as compared with the corresponding period of the previous year. As at the end of the third quarter of 2022, the SMO business maintained more than 4,700 staff across around 150 cities in China, providing services at more than 1,000 hospitals. From January to September 2022, SMO supported 23 new drug approvals.

- (3) Our biology business (WuXi Biology) realized revenue of RMB1,779.4 million in the first three quarters of 2022, representing a YoY growth of 24.9% as compared to the revenue of RMB1,424.3 million in the same period of 2021. Although revenue growth in the second quarter was temporarily impacted by the ongoing effects of the COVID-19 epidemic in Shanghai, business recovered in the third quarter due to the dedication of our employees. The Company has one of the largest discovery biology enabling platform, with more than 2,800 experienced scientists who provide comprehensive biology services and solutions covering all major stages and therapeutic areas of drug discovery. The Company has established three centers of excellence for non-alcoholic steatohepatitis (NASH), anti-viral, neuroscience and aging. Cancer discovery service, rare and immune disease service also continued to grow, providing customers with integrated high-quality services from target discovery to clinical biomarker detection. The Company has a leading DNA Encoded Library (DEL) and hit compound generation platform, providing service for more than 1,300 customers. A customer advanced a project into clinical stage based on the hits generated using our DEL screening technology. This is the first reported clinical candidate from our DEL hits, which is also an important validation of our platform. The Company continues to build its biology capabilities for new modalities, including target protein degradation, nucleic acid based and conjugated modalities, oncolytic virus, vector platforms, and novel drug delivery vehicles. From January to September 2022, revenue from new modalities and large molecules grew by 76%, and its revenue contribution rose to 20.5% in the first three quarters of 2022, from 14.6% in 2021, suggesting that new modalities-related biology services have become an increasingly important growth driver.

- (4) Our cell and gene therapy CTDMO business (WuXi ATU) realized revenue of RMB921.6 million in the first three quarters of 2022, representing a YoY increase of 25.2% as compared to the revenue of RMB735.9 million in the same period of 2021. Revenue from Testing service grew 44%, and revenue from Development service grew 54%. The Company further strengthened the capabilities in product testing, process development and production of cell and gene therapy products. It provided development and manufacturing services for 67 projects, including 50 clinical testing projects in preclinical stage and Phase I, 9 clinical testing projects in Phase II, and 8 clinical testing projects in Phase III (4 projects are in biological license application (BLA) preparation stage). As at the date of this announcement, we have supported two BLA filings on behalf of our clients, including one for tumor-infiltrating lymphocytes (TILs) from an US-based client and one for Lentiviral vector used for CAR-T product from a China-based client. The Company announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™) in March 2022. TESSA™ technology is a revolutionary and novel process for transfection-free, scalable manufacturing of adeno-associated virus (AAV). Process has now been scaled to 200L that produces more than 10 times AAV products compared to traditional plasmid-based manufacture. In August 2022, we announced a licensing agreement with Janssen for TESSA™ Technology. As at September 30, 2022, we had 38 TESSA™ evaluation projects by customers, including 6 large biotech/pharmaceutical companies.
- (5) Our domestic new drug discovery services business (WuXi DDSU) realized revenue of RMB671.8 million in the first three quarters of 2022, representing a YoY decrease of 27.9% as compared to RMB931.8 million in the same period of 2021. The revenue decline was mainly attributable to business evolution that aims to better serve the growing needs of clients in China for novel and innovative products. From January to September 2022, the Company helped customers complete IND filing process for 15 projects and obtained 26 clinical trial approvals. As at the end of the third quarter of 2022, the Company had completed IND filings for 159 projects and obtained clinical trial approvals for 136 projects. In addition, new drug application (NDA) for 1 project was in progress, and there were 5 projects, 21 projects and 77 projects in Phase III, Phase II and Phase I clinical trials, respectively. Upon the launch of customers' products, we will receive a commission according to the agreed percentage of the drug revenue of customers pursuant to the agreements. We are now putting our efforts towards the discovery of potential best-in-class molecules and new modalities molecules for customers. Currently, we are working for customers on 15 pre-clinical projects in new modalities that include Peptide/Peptide-Drug-Conjugation (PDC), protein degraders and oligonucleotides. Several of these projects are expected to file an IND application in late 2022 or early 2023.

Analysis note:

Net cash flows from operating activities

The net cash flow from operating activities of the Company for the first three quarters of 2022 amounted to RMB7,709.7 million, representing a YoY growth of 142%. The unique CRDMO and CTDMO business models of the Company continue to successfully drive record high financial performance. The business of the Company continued its healthy growth while large scale commercialization production projects generated strong cash flow. The Company has decided to terminate the proposed issuance of H shares which obtained the approval by the CSRC on August 17, 2022.

The Company is confident to adjust the revenue growth target for the full year of 2022 from the previously announced 68%-72% (as disclosed in the relevant announcement of the Company dated July 22, 2022) to 70%-72%, reflecting the Company's confidence in its continuous accelerated growth driven by CRDMO and CTDMO business models.

Note:

The abovementioned operating performance forecast for 2022 is made based on the current order backlog of the Company. In addition, such operating performance forecast is subject to various prerequisites, including the continued stabilization or improvement of the COVID-19 global pandemic, the stable development of the global pharmaceutical industry and the stability of the international trade environment and regulatory environment of the countries where the main operations of the Company are located. Further, such operating performance forecast does not constitute a profit forecast by the management of the Company for the full year of 2022 nor a substantive undertaking by the Company to investors. Its realization is subject to various factors including but not limited to changes in internal and external environment, where greater uncertainty exists.

IV. Information about shareholders

1. Total number of ordinary shareholders, total number of preference shareholders with voting rights restored and shareholdings of the top 10 shareholders as at the end of the Reporting Period

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	303,841
Total number of preference shareholders with voting rights restored at the end of the Reporting Period (if any)	Nil

Shareholdings of top 10 Shareholders

Full name of shareholders	Nature of shareholders	Number of Shares held as at the end of the Reporting Period	Percentage (%)	Number of Shares subject to trading restrictions	Pledged, marked or frozen Shares Status	Number
HKSCC NOMINEES LIMITED ^(Note 1)	Overseas legal entity	395,221,918	13.3502	0	Unknown	0
Hong Kong Securities Clearing Company Limited ^(Note 2)	Overseas legal entity	187,809,068	6.3440	0	Unknown	0
G&C VI Limited	Overseas legal entity	183,058,916	6.1835	0	Nil	0
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	Overseas legal entity	159,160,073	5.3763	0	Nil	0
G&C IV Hong Kong Limited	Overseas legal entity	133,919,072	4.5237	0	Nil	0
G&C V Limited	Overseas legal entity	93,573,546	3.1608	0	Nil	0
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) (北京中民銀孚投資管理有限公司 — 嘉興宇祥投資合夥企業(有限合夥))	Other	87,074,568	2.9413	0	Nil	0
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療健康混合型證券投資基金)	Other	61,885,072	2.0904	0	Nil	0
China Life Insurance Company Limited — Traditional — General Insurance Products — 005L — CT001 Hu (中國人壽保險股份有限公司 — 傳統 — 普通保險產品 — 005L — CT001滬)	Other	55,364,421	1.8702	0	Nil	0
G&C VII Limited	Overseas legal entity	48,450,340	1.6366	0	Nil	0

Shareholdings of top 10 holders of Shares not subject to trading restrictions

Full name of shareholder	Number of Shares not subject to trading restrictions	Class and number of Shares	
		Class	Number
HKSCC NOMINEES LIMITED ^(Note 1)	395,221,918	Overseas-listed foreign shares	395,221,918
Hong Kong Securities Clearing Company Limited ^(Note 2)	187,809,068	RMB-denominated ordinary shares	187,809,068
G&C VI Limited	183,058,916	RMB-denominated ordinary shares	183,058,916
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	159,160,073	RMB-denominated ordinary shares	159,160,073
G&C IV Hong Kong Limited	133,919,072	RMB-denominated ordinary shares	133,919,072
G&C V Limited	93,573,546	RMB-denominated ordinary shares	93,573,546
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) (北京中民銀孚投資管理有限公司 — 嘉興宇祥投資合夥企業(有限合夥))	87,074,568	RMB-denominated ordinary shares	87,074,568
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療健康混合型證券投資基金)	61,885,072	RMB-denominated ordinary shares	61,885,072
China Life Insurance Company Limited — Traditional — General Insurance Products — 005L — CT001 Hu (中國人壽保險股份有限公司 — 傳統 — 普通保險產品 — 005L — CT001滬)	55,364,421	RMB-denominated ordinary shares	55,364,421
G&C VII Limited	48,450,340	RMB-denominated ordinary shares	48,450,340
Description of connected relationships or concerted actions of the above shareholders	G&C VI Limited, G&C IV Hong Kong Limited, G&C V Limited, G&C VII Limited, and Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) being part of the top 10 shareholders of the Company, are acting in concert.		
The participation of top 10 shareholders and top 10 shareholders holding Shares not subject to trading restrictions in financing, financial notes and financial institution backed securities business (if any)	Not applicable		

Note 1: HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

Note 2: Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB denominated ordinary shares under the Shanghai-Hong Kong Stock Connect.

V. Other reminders

Other important information about the Company's operating conditions during the Reporting Period that investors need to be reminded of and pay attention to.

Applicable Not applicable

VI. Quarterly financial statements

1. Type of auditor's opinion

Applicable Not applicable

2. Financial statements

Consolidated Balance Sheet

As at September 30, 2022

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item	As at September 30, 2022	As at December 31, 2021
Current Assets:		
Bank balances and cash	9,214,256,461.06	8,238,772,782.53
Financial assets held for trading	70,204,933.93	527,288,380.38
Derivative financial assets	—	229,142,186.76
Note receivables	99,500,335.63	48,000,000.00
Trade receivables	6,071,194,200.86	4,619,550,091.65
Prepayments	305,323,722.93	302,910,091.83
Other receivables	202,075,368.71	339,579,823.47
Including: Interest receivables	—	38,280.82
Dividend receivables	—	—
Inventories	6,581,305,658.96	5,905,005,712.92
Contract assets	948,475,554.99	773,432,779.63
Non-current assets due within one year	550,616,424.71	—
Other current assets	1,412,776,965.83	1,001,966,753.16
Total Current Assets	25,455,729,627.61	21,985,648,602.33

Item	As at September 30, 2022	As at December 31, 2021
Non-current Assets:		
Long-term equity investments	1,162,933,031.27	678,304,556.75
Other non-current financial assets	9,402,008,757.74	8,714,098,195.97
Fixed assets	12,010,228,742.44	8,553,875,239.51
Construction in progress	8,109,254,920.82	5,771,792,447.77
Productive biological assets	940,457,000.00	733,510,000.00
Right-of-use assets	1,042,328,170.63	1,069,566,509.12
Intangible assets	1,698,237,823.10	1,599,754,747.41
Goodwill	1,934,225,612.25	1,925,563,131.98
Long-term deferred expenditures	1,689,316,937.81	1,539,454,173.75
Deferred tax assets	619,578,903.92	389,846,300.63
Other non-current assets	1,684,917,233.91	2,165,974,478.81
Total Non-current Assets	40,293,487,133.89	33,141,739,781.70
Total Assets	65,749,216,761.50	55,127,388,384.03
Current Liabilities:		
Short-term borrowings	3,173,210,056.00	2,261,479,950.00
Derivative financial liabilities	1,290,202,998.04	3,651,608.46
Note payables	28,926,266.34	—
Trade payables	1,813,100,441.26	1,931,006,166.97
Contract liabilities	3,959,048,700.05	2,986,378,875.46
Payroll payables	1,694,481,153.87	1,580,451,651.57
Tax payables	1,139,424,628.51	536,009,384.72
Other payables	3,946,817,567.58	3,289,192,625.17
Including: Interest payables	1,757,052.38	1,337,744.33
Dividend payables	—	—
Non-current liabilities due within one year	428,644,603.83	396,423,607.05
Total Current Liabilities	17,473,856,415.48	12,984,593,869.40

Item	As at September 30, 2022	As at December 31, 2021
Non-current Liabilities:		
Long-term borrowings	373,235,350.00	—
Bond payables	507,046,246.92	607,140,031.37
Including: Preference shares	—	—
Perpetual bonds	—	—
Lease liabilities	1,004,463,649.47	1,018,978,731.37
Deferred income	871,471,842.21	770,600,758.25
Deferred tax liabilities	341,795,005.00	324,125,305.36
Other non-current liabilities	40,260,857.72	664,487,072.47
Total Non-current Liabilities	3,138,272,951.32	3,385,331,898.82
Total Liabilities	20,612,129,366.80	16,369,925,768.22
Owners' Equity (or Shareholders' Equity):		
Paid-in capital (or share capital)	2,960,419,498.00	2,955,826,899.00
Capital reserve	26,717,726,814.42	25,731,889,443.00
Less: Treasury shares	2,259,920,708.75	2,459,221,426.68
Other comprehensive income	-1,011,547,394.45	-271,422,544.97
Special reserve	—	—
Surplus reserve	408,358,883.50	408,358,883.50
Undistributed profit	17,994,997,571.35	12,126,078,376.75
Total Equity (or Shareholders' Equity)		
attributable to owners of the Company	44,810,034,664.07	38,491,509,630.60
Non-controlling interests	327,052,730.63	265,952,985.21
Total Owners' Equity (or Shareholders' Equity)	45,137,087,394.70	38,757,462,615.81
Total Liabilities and Owners' Equity (or Shareholders' Equity)	65,749,216,761.50	55,127,388,384.03
Person in charge of the Company:	Ge Li	
Chief Financial Officer:	Ming Shi	
Director of the Accounting Department:	Jin Sun	

Consolidated Income Statement

January to September 2022

Prepared by: WuXi AppTec Co., Ltd

Unit: RMB Type of audit: Unaudited

Item	First three quarters of 2022 (January – September)	First three quarters of 2021 (January – September)
I. Total revenue	28,394,561,790.41	16,521,369,391.37
Including: Revenue	28,394,561,790.41	16,521,369,391.37
II. Total cost	21,159,921,597.90	13,137,666,500.63
Including: Cost	17,853,755,830.08	10,410,754,419.19
Taxes and surcharges	90,706,491.42	33,881,553.53
Selling expenses	555,299,587.48	497,157,806.57
Administrative expenses	2,040,026,783.97	1,505,726,229.89
Research and development expenses	1,089,268,152.01	644,205,887.55
Finance expenses	-469,135,247.06	45,940,603.90
Including: Interest expense	70,546,311.05	52,374,900.98
Interest income	118,541,636.91	144,266,882.07
Add: Other income	224,609,998.02	141,829,750.60
Investment gains (“-” indicating loss)	420,983,118.79	1,374,368,868.83
Including: Gains from investments in associates and joint ventures	-107,257,206.20	-3,628,628.90
Gains from changes in fair value (“-” indicating loss)	1,095,201,959.52	-547,860,299.26
Credit impairment losses (“-” indicating loss)	-91,474,117.90	-23,159,137.74
Assets impairment losses (“-” indicating loss)	-34,482,484.73	-19,721,174.11
Gains on assets disposal (“-” indicating loss)	-7,282,339.87	-6,848,946.32
III. Operating profit (“-” indicating loss)	8,842,196,326.34	4,302,311,952.74
Add: Non-operating income	6,239,512.33	6,507,568.77
Less: Non-operating expenses	29,166,086.82	26,147,910.86
IV. Total profit (“-” indicating total loss)	8,819,269,751.85	4,282,671,610.65
Less: Income tax expenses	1,372,652,145.65	694,427,828.13

Item	First three quarters of 2022 (January – September)	First three quarters of 2021 (January – September)
V. Net profit (“-” indicating net loss)	7,446,617,606.20	3,588,243,782.52
(I) Classified by continuity of operations		
1. Net profit from continuing operations (“-” indicating net loss)	7,446,617,606.20	3,588,243,782.52
2. Net profit from discontinued operations (“-” indicating net loss)	—	—
(II) Classified by ownership		
1. Net profit attributable to the owners of the Company (“-” indicating net loss)	7,377,913,928.98	3,562,226,936.53
2. Profit attributable to non-controlling shareholders (“-” indicating net loss)	68,703,677.22	26,016,845.99
VI. Other comprehensive income, net of tax	-752,051,759.33	-396,270,807.97
(I) Other comprehensive income attributable to owners of the Company, net of tax	-740,124,849.48	-393,066,320.01
1. Other comprehensive income that will not be reclassified to profit or loss	—	—
(1) Changes in re-measurement of defined benefit plans	—	—
(2) Other comprehensive income that will not be transferred to profit or loss accounted for using equity method	—	—
(3) Changes in fair value of investments in other equity instruments	—	—
(4) Changes in fair value of the Company’s own credit risk	—	—
2. Other comprehensive income that will be reclassified to profit or loss	-740,124,849.48	-393,066,320.01
(1) Other comprehensive income that will be transferred to profit or loss accounted for using equity method	—	—
(2) Changes in fair value of other debt investments	—	—

Item	First three quarters of 2022 (January – September)	First three quarters of 2021 (January – September)
(3) Financial assets reclassified to other comprehensive income	—	—
(4) Credit impairment allowance of other debt investments	—	—
(5) Cash flow hedging reserve	-1,277,712,903.20	-335,476,361.54
(6) Exchange difference on translation of foreign financial statements	537,588,053.72	-57,589,958.47
(7) Others	—	—
(II) Other comprehensive income attributable to non-controlling shareholders, net of tax	-11,926,909.85	-3,204,487.96
VII. Total comprehensive income	6,694,565,846.87	3,191,972,974.55
(I) Total comprehensive income attributable to owners of the Company	6,637,789,079.50	3,169,160,616.52
(II) Total comprehensive income attributable to non-controlling shareholders	56,776,767.37	22,812,358.03
VIII. Earnings per share:		
(I) Basic earnings per share (RMB per share)	2.52	1.22
(II) Diluted earnings per share (RMB per share)	2.30	1.21

For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was nil (corresponding period of the previous year: nil).

Person in charge of the Company:	Ge Li
Chief Financial Officer:	Ming Shi
Director of the Accounting Department:	Jin Sun

Consolidated Statement of Cash Flows

January to September 2022

Prepared by: WuXi AppTec Co., Ltd.

	Unit: RMB	Type of audit: Unaudited
Item	First three quarters of 2022 (January – September)	First three quarters of 2021 (January – September)
I. Cash flow from operating activities:		
Cash received from sale of goods or rendering of services	29,493,538,739.88	16,823,642,634.30
Refunds of taxes and surcharges	1,002,407,672.17	567,694,786.51
Cash received relating to other operating activities	398,595,973.58	495,326,757.35
Sub-total of cash inflow from operating activities	30,894,542,385.63	17,886,664,178.16
Cash paid for purchasing goods and receiving services	13,452,305,984.43	7,583,830,606.03
Cash paid to and on behalf of employees	7,177,292,652.12	5,385,637,870.15
Payments of taxes and surcharges	1,057,217,973.26	697,993,885.70
Cash paid relating to other operating activities	1,498,075,227.33	1,038,426,006.93
Sub-total of cash outflow from operating activities	23,184,891,837.14	14,705,888,368.81
Net cash flow generated from operating activities	7,709,650,548.49	3,180,775,809.35
II. Cash flow from investing activities:		
Cash received from disposal of investments	1,320,850,794.30	3,119,237,661.99
Cash received from return on investments	72,780,787.76	105,273,599.29
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	294,791,691.52	3,114,416.24
Net cash received from disposal of subsidiaries and other business entities	—	—
Cash received relating to other investing activities	—	—
Sub-total of cash inflow from investing activities	1,688,423,273.58	3,227,625,677.52
Cash paid to acquire fixed assets, intangible assets and other long-term assets	6,746,412,720.88	4,830,368,492.06
Cash paid to acquire investments	1,035,634,022.34	1,812,320,451.48
Net cash paid to acquire subsidiaries and other business entities	—	857,689,819.74
Cash paid relating to other investing activities	21,193,032.64	—
Sub-total of cash outflow from investing activities	7,803,239,775.86	7,500,378,763.28
Net cash flow from investing activities	-6,114,816,502.28	-4,272,753,085.76

Item	First three quarters of 2022 (January – September)	First three quarters of 2021 (January – September)
III. Cash flow from financing activities:		
Cash received from capital contributions:	63,670,747.14	90,644,107.94
Including: Cash received from capital contribution by non-controlling shareholders of subsidiaries	—	—
Cash received from borrowings	2,162,537,303.81	2,279,299,450.00
Cash received relating to other financing activities	—	—
Sub-total of cash inflow from financing activities	2,226,208,050.95	2,369,943,557.94
Cash repayments of borrowings	1,138,983,410.21	1,209,543,500.00
Cash payments for distribution of dividends, profits or interest expenses	1,572,965,368.08	907,880,921.69
Including: Dividends and profits paid by subsidiaries to non-controlling shareholders	—	3,400,000.00
Cash paid relating to other financing activities	213,568,167.72	1,853,665,355.30
Sub-total of cash outflow from financing activities	2,925,516,946.01	3,971,089,776.99
Net cash flow generated from financing activities	-699,308,895.06	-1,601,146,219.05
IV. Effect of fluctuations in exchange rates on cash and cash equivalents	143,095,323.49	-32,290,311.06
V. Net increase in cash and cash equivalents	1,038,620,474.64	-2,725,413,806.52
Add: Balance of cash and cash equivalents at the beginning of the period	8,175,335,986.42	10,228,057,054.30
VI. Balance of cash and cash equivalents at the end of the period	9,213,956,461.06	7,502,643,247.78

Person in charge of the Company: Ge Li
Chief Financial Officer: Ming Shi
Director of the Accounting Department: Jin Sun

3. Adjustments on the financial statements at the beginning of the first year of adopting new leasing standards since 2022

Applicable Not applicable

4. Quarterly condensed consolidated financial statements prepared in accordance with IFRSs

Consolidated Statement of Profit or Loss and Other Comprehensive Income
January to September 2022

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	Third quarter of 2022 (July – September)	Third quarter of 2021 (July – September)	First three quarters of 2022 (January – September)	First three quarters of 2021 (January – September)
Revenue	10,638,304	5,984,811	28,394,562	16,521,369
Cost of services	(6,600,180)	(3,784,733)	(17,929,613)	(10,437,564)
Gross profit	4,038,124	2,200,078	10,464,949	6,083,805
Other income	113,264	80,575	353,813	286,652
Other gains and losses	668,443	(24,265)	2,058,328	716,338
Impairment losses under expected credit losses (“ECL”) model, net of reversal	(35,209)	(1,515)	(93,959)	(23,159)
Selling and marketing expenses	(199,686)	(141,899)	(555,300)	(497,158)
Administrative expenses	(791,339)	(543,060)	(2,099,150)	(1,538,336)
Research and development expenses	(432,068)	(239,775)	(1,089,268)	(644,206)
Operating profit	3,361,529	1,330,139	9,039,413	4,383,936
Share of results of associates	(35,977)	(201,662)	(106,812)	15,624
Share of results of joint ventures	(1,880)	3,041	(446)	(19,252)
Finance costs	(45,264)	(28,781)	(112,885)	(97,636)
Profit before tax	3,278,408	1,102,737	8,819,270	4,282,672
Income tax expense	(507,449)	(206,686)	(1,372,652)	(694,428)
Profit for the period	2,770,959	896,051	7,446,618	3,588,244

	Third quarter of 2022 (July – September)	Third quarter of 2021 (July – September)	First three quarters of 2022 (January – September)	First three quarters of 2021 (January – September)
Other comprehensive income (expense) for the period				
<i>Items that may be reclassified subsequently to profit or loss:</i>				
Exchange differences on translation of financial statements of foreign operations	253,703	13,288	536,288	(58,251)
Fair value losses on hedging instrument designated in cash flow hedges	<u>(707,167)</u>	<u>(132,417)</u>	<u>(1,288,340)</u>	<u>(338,020)</u>
Other comprehensive expense for the period, net of income tax	<u>(453,464)</u>	<u>(119,129)</u>	<u>(752,052)</u>	<u>(396,271)</u>
Total comprehensive income for the period	<u>2,317,495</u>	<u>776,922</u>	<u>6,694,566</u>	<u>3,191,973</u>
Profit for the period attributable to:				
Owners of the Company	2,742,165	887,126	7,377,914	3,562,227
Non-controlling interests	<u>28,794</u>	<u>8,925</u>	<u>68,704</u>	<u>26,017</u>
	<u>2,770,959</u>	<u>896,051</u>	<u>7,446,618</u>	<u>3,588,244</u>
Total comprehensive income for the period attributable to:				
Owners of the Company	2,295,330	769,156	6,637,789	3,169,161
Non-controlling interests	<u>22,165</u>	<u>7,766</u>	<u>56,777</u>	<u>22,812</u>
	<u>2,317,495</u>	<u>776,922</u>	<u>6,694,566</u>	<u>3,191,973</u>
Earnings per share (expressed in RMB per share)				
— Basic	<u>0.93</u>	<u>0.30</u>	<u>2.52</u>	<u>1.22</u>
— Diluted	<u>0.81</u>	<u>0.30</u>	<u>2.30</u>	<u>1.21</u>

Consolidated Statement of Financial Position

As at September 30, 2022

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	As at September 30, 2022	As at December 31, 2021
Non-current Assets		
Property, plant and equipment	21,795,768	15,848,703
Right of use assets	1,861,985	1,779,500
Goodwill	1,934,226	1,925,563
Other intangible assets	878,581	889,822
Interest in associates	1,101,908	619,382
Interest in joint ventures	61,025	58,923
Financial assets at fair value through profit or loss (“FVTPL”)	9,402,009	8,714,098
Deferred tax assets	619,579	389,846
Other non-current assets	1,697,949	2,182,393
Biological assets	940,457	733,510
	40,293,487	33,141,740
Total Non-current Assets		
Current Assets		
Inventories	5,123,607	4,554,577
Trade and other receivables	8,009,201	5,968,471
Contract assets	948,476	773,433
Contract costs	455,034	594,912
Biological assets	1,002,665	755,517
Income tax recoverable	225	225
Financial assets at FVTPL	70,205	527,288
Amounts due from related parties	81,445	343,310
Derivative financial instruments	—	229,142
Other current assets	550,616	—
Pledged bank deposits	300	63,437
Bank balances and cash	9,213,956	8,175,336
	25,455,730	21,985,648
Total Current Assets		
	65,749,217	55,127,388
Total Assets		

	As at September 30, 2022	As at December 31, 2021
Current Liabilities		
Trade and other payables	7,740,420	6,855,964
Income tax payables	871,777	459,256
Amounts due to related parties	10,552	21,439
Borrowings	3,173,210	2,261,480
Lease liabilities	246,784	220,183
Derivative financial instruments	1,290,203	3,652
Contract liabilities	3,959,049	2,986,379
Other current liabilities	181,861	176,241
	<hr/>	<hr/>
Total Current Liabilities	17,473,856	12,984,594
	<hr/>	<hr/>
Non-current Liabilities		
Deferred tax liabilities	341,795	324,125
Deferred income	871,472	770,601
Lease liabilities	1,004,464	1,018,979
Convertible bonds — debt component	507,046	607,140
Convertible bonds — derivative component	40,211	657,317
Borrowings	373,235	—
Other long-term liabilities	50	7,170
	<hr/>	<hr/>
Total Non-current Liabilities	3,138,273	3,385,332
	<hr/>	<hr/>
Total Liabilities	20,612,129	16,369,926
	<hr/>	<hr/>
Capital and Reserves		
Share capital	2,960,419	2,955,827
Reserves	41,849,616	35,535,682
	<hr/>	<hr/>
Equity attributable to owners of the Company	44,810,035	38,491,509
Non-controlling interests	327,053	265,953
	<hr/>	<hr/>
Total Equity	45,137,088	38,757,462
	<hr/> <hr/>	<hr/> <hr/>

Consolidated Statement of Cash Flows

January to September 2022

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	First three quarters of 2022 (January – September)	First three quarters of 2021 (January – September)
Net cash from operating activities	7,430,657	3,069,256
Investing activities		
Interests received	56,250	86,617
Proceeds from disposal of financial assets at FVTPL	1,337,325	3,909,223
Purchase of financial assets at FVTPL	(506,218)	(1,751,582)
Purchase of other non-current assets	—	(700,000)
Proceeds from disposal of property, plant and equipment and business	293,577	2,255
Proceeds from disposal of other intangible assets	1,214	858
Acquisition of interests in associates/investment in associates	(529,416)	(49,646)
Purchase of property, plant and equipment	(6,624,337)	(4,696,616)
Purchase of right-of-use assets	(118,988)	—
Purchase of other intangible assets	(3,087)	(2,819)
Purchase of biological assets	—	(130,934)
Withdraw of pledged bank deposits	63,137	239
Net cash outflow on acquisition of subsidiaries	—	(857,690)
Net cash outflow on deemed disposal of subsidiaries	(21,193)	—
Dividends received from associates	32,480	11,222
Dividends received from financial assets at FVTPL	23,826	4,069
Payment for forward contracts	(1,897)	(11,092)
Payment for rental deposits	(10,894)	(17,578)
R&D grants and others received related to assets	161,504	42,240
Net cash used in operating activities	(5,846,717)	(4,161,234)

	First three quarters of 2022	First three quarters of 2021
Financing Activities		
Payment of dividends	(1,529,442)	(892,980)
New borrowings raised	2,162,537	2,279,299
Repayment of borrowings	(1,138,982)	(1,209,543)
Acquisition of partial interest of subsidiaries from non-controlling shareholders	(32,668)	(13,621)
Net proceeds from exercise of stock option	63,671	90,644
Interests paid	(43,524)	(14,901)
Repayment of lease liabilities	(166,640)	(167,201)
Issue cost paid	—	(1,318)
Repurchase and cancellation of restricted A Shares	(3,367)	(5,405)
Repurchase of H shares for share incentive scheme	—	(1,666,120)
	<u>(688,415)</u>	<u>(1,601,146)</u>
Net cash used in financing activities		
	895,525	(2,693,124)
Net increase(decrease) in cash and cash equivalents		
Cash and cash equivalents at the beginning of the period	8,175,336	10,228,057
Effects of exchange rate changes	143,095	(32,290)
	<u>9,213,956</u>	<u>7,502,643</u>
Cash and cash equivalents at the end of the period		

5. Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company

Unit: RMB'000 Type of audit: Unaudited

	Third quarter of 2022 (July – September)	Third quarter of 2021 (July – September)	First three quarters of 2022 (January – September)	First three quarters of 2021 (January – September)
Profit attributable to the owners of the Company	2,742,165	887,126	7,377,914	3,562,227
Add:				
Share-based compensation expenses	143,410	108,437	503,413	419,080
Issuance expenses of Convertible Bonds	438	540	1,296	2,370
Fair value (gain) loss from derivative component of Convertible Bonds	(342,542)	(24,463)	(617,051)	1,468,877
Foreign exchange related (gains) losses	(207,418)	6,675	(365,948)	73,444
Amortization of acquired intangible assets from merge and acquisition	13,831	14,911	42,482	41,068
Non-IFRS net profit attributable to the owners of the Company	<u>2,349,884</u>	<u>993,226</u>	<u>6,942,105</u>	<u>5,567,066</u>
Add:				
Realized and unrealized losses (gains) from venture capital investments	119,705	368,168	(170,382)	(1,779,985)
Realized and unrealized share of losses (gains) from joint ventures	1,880	(3,041)	446	19,252
Adjusted non-IFRS net profit attributable to the owners of the Company	<u>2,471,469</u>	<u>1,358,352</u>	<u>6,772,168</u>	<u>3,806,332</u>

Notes:

The discrepancies between the total and sums of amounts in the table above are due to rounding.